<DOC>
	<DOCNO>NCT00480090</DOCNO>
	<brief_summary>This single-arm , open label phase II trial investigational agent , Ara-C ( cytarabine ) , patient diagnose hormone refractory prostate cancer whose disease progress deem suitable standard chemotherapy docetaxel . Ara-C appear inhibit DNA synthesis cytotoxic wide variety mammalian cell . Recent discovery suggest role gene fusion ETS family transcription factor important development prostate cancer . Ara-C appear block ETS gene , suggest worthwhile explore Ara-C potential new treatment patient hormone refractory prostate cancer give standard care propose patient population . In study , Ara-C administer intravenously 2 day every 3 week ( 1 cycle ) . Treatment 6 cycle tolerate may continue patient respond severe toxicity .</brief_summary>
	<brief_title>A Phase II Study Ara-C ( Cytarabine ) Men With Androgen Independent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Biopsyproven prostate cancer clinical picture consistent metastatic prostate cancer high level serum PSA ( &gt; 20ng/ml ) At least 4 week docetaxel treatment least 2 consecutive rise PSAs measure least 2 week apart Progression intolerance docetaxel chemotherapy ECOG performance status â‰¤ 2 Adequate organ marrow function Prior treatment cytarabine Receiving investigational anticancer agent Uncontrolled intercurrent illness Active malignancy site exclude squamous cell basal cell carcinoma skin Radiotherapy within past 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Androgen independent</keyword>
	<keyword>Phase II</keyword>
	<keyword>Second line</keyword>
	<keyword>Androgen-independent prostate cancer</keyword>
</DOC>